Form 4: UTHR Director Exercises Options, Sells Shares
Insider Transaction Report
Christopher Causey, a director at United Therapeutics Corp, exercised stock options and subsequently sold 1,000 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Christopher Causey, a Director of United Therapeutics Corp (UTHR), engaged in an insider transaction.
- On January 2, 2026, Causey exercised 1,000 stock options at an exercise price of $119.76 per share.
- Concurrently, he sold 1,000 shares of common stock at a weighted average price of $500.0146 per share.
- The transactions were executed pursuant to a Rule 10b5-1 trading plan established on September 30, 2025.
- Following these transactions, Causey directly beneficially owns 4,190 shares of common stock and 8,320 stock options.
Sentiment
Score: 6
Explanation: The transaction is a routine insider sale under a pre-arranged 10b5-1 plan, which is generally viewed as neutral. The director realized a substantial profit, which is positive for the individual, but the sale itself is not a strong indicator for the company's future performance.
Positives
- The director realized a significant profit from exercising options and selling shares, with a sale price substantially higher than the exercise price.
- The transaction was conducted under a Rule 10b5-1 trading plan, indicating pre-planning and reducing concerns about opportunistic insider selling.
Negatives
- A director selling shares, even under a 10b5-1 plan, could be interpreted by some as a lack of conviction in the company's near-term stock price appreciation, though this is mitigated by the pre-scheduled nature.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | The transactions were conducted under a Rule 10b5-1 trading plan, which is a corporate governance mechanism allowing insiders to pre-arrange stock trades to avoid accusations of insider trading. | 09/30/2025 | Enhances transparency and reduces potential for perceived opportunistic insider trading. |
Stakeholder Impact
- Shareholders: The sale of shares by a director could be a minor signal, but its execution under a 10b5-1 plan mitigates concerns about its implications for future stock performance.
Key Dates
| Date | Description |
|---|---|
| 06/26/2021 | Grant date of the stock options. |
| 09/30/2025 | Date the Rule 10b5-1 trading plan was entered into by the reporting person. |
| 01/02/2026 | Date of stock option exercise and subsequent sale of common stock. |
| 01/05/2026 | Date the Form 4 was signed. |
| 06/26/2030 | Expiration date of the stock options. |
Recommendation
holdThis Form 4 reports a routine, pre-scheduled insider transaction (exercise of options and sale of shares) under a Rule 10b5-1 plan. Such transactions are generally not considered highly price-sensitive or indicative of a significant change in the company's fundamental outlook. While the director realized a profit, this is a personal financial event rather than a corporate strategic move. Therefore, it does not warrant a change in investment recommendation based solely on this filing.
Keywords
United Therapeutics, UTHR, Form 4, insider transaction, stock options, share sale, Rule 10b5-1, director, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.